Page last updated: 2024-12-06

prazosin hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Prazosin hydrochloride is an α1-adrenergic receptor antagonist that is used to treat hypertension and benign prostatic hyperplasia. It was first synthesized in 1966 and is currently available as a generic drug. Prazosin hydrochloride works by blocking the action of norepinephrine and epinephrine, which are hormones that cause blood vessels to constrict. This blockade results in vasodilation, which lowers blood pressure. The drug has also been found to be effective in treating symptoms of benign prostatic hyperplasia, such as difficulty urinating. Prazosin hydrochloride is typically well-tolerated, but it can cause side effects such as dizziness, lightheadedness, and headache. In some cases, it can also cause orthostatic hypotension, which is a sudden drop in blood pressure when standing up. Prazosin hydrochloride is an important drug for the treatment of hypertension and benign prostatic hyperplasia, and it is the subject of ongoing research to explore its potential use in other conditions such as post-traumatic stress disorder and sleep apnea. '

Cross-References

ID SourceID
PubMed CID68546
CHEMBL ID1558
CHEBI ID8365
SCHEMBL ID41257
MeSH IDM0544014

Synonyms (124)

Synonym
AC-699
piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-, monohydrochloride
einecs 242-903-4
c19h21n5o4.hcl
peripress
furazosin hydrochloride
minipress xl
hypovasole
quinazoline, 4-amino-6,7-dimethoxy-2-(4-(2-furoyl)piperazin-1-yl)-, hydrochloride
prazosin hcl
piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-, monohydrochloride
hypovase
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine hydrochloride
2-(4-(2-furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline hydrochloride
pratsiol
cp-12299-1
prazosin clorhidrato [spanish]
deprazolin
nsc 292810
sinetens
MLS001148201
MLS002153280
MLS001333696
CHEBI:8365 ,
EU-0101002
prazosin hydrochloride, >=99% (tlc)
1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)piperazine monohydrochloride
vasoflex
nsc-292810
prazosin hydrochloride
minipress
piperazine,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)-, monohydrochloride
cp-12,299-1
19237-84-4
nsc292810
piperazine,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-, monohydrochloride
hsdb 3298
prazosin hydrochloride (jp17/usp)
D00609
NCGC00094296-03
NCGC00094296-02
smr000058384
MLS000028454 ,
SPECTRUM1500495
NCGC00094296-01
NCGC00094296-05
NCGC00094296-04
hydrochloride, prazosin
hcl, prazosin
MLS002222304
CHEMBL1558
P0938
HMS1920J10
HMS1570N16
unii-x0z7454b90
x0z7454b90 ,
prazosin hydrochloride [usan:usp:jan]
nsc-757286
nsc757286
pharmakon1600-01500495
CCG-39227
(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(furan-2-yl)methanone hydrochloride
alpress lp
LP01002
prazosin hydrochloride [ep monograph]
prazosin hydrochloride [usp monograph]
minizide component prazosin hydrochloride
prazosin hydrochloride [usan]
prazosin hydrochloride [hsdb]
prazosin hydrochloride [ep impurity]
prazosin hydrochloride [orange book]
prazosin hydrochloride [who-dd]
prazosin hydrochloride [usp-rs]
prazosin hydrochloride [jan]
prazosin hydrochloride component of minizide
prazosin hydrochloride [mart.]
prazosin hydrochloride [mi]
prazosin hydrochloride [vandf]
S1424
AKOS015895394
prazosin (hydrochloride)
HY-B0193A
SCHEMBL41257
AF-0012
tox21_501002
NCGC00261687-01
prazosine hydrochloride
WFXFYZULCQKPIP-UHFFFAOYSA-N
W-107719
1-(4-amino-6,7-dimethoxy-2-quinazol inyl)-4-(2-furanylcarbonyl)piperazine hydrochloride
HB2767
prazosin hydrochloride;
OPERA_ID_370
DTXSID50172822 ,
mfcd00058177
prazosin hydrochloride, united states pharmacopeia (usp) reference standard
prazosin hydrochloride, european pharmacopoeia (ep) reference standard
SR-01000003052-2
SR-01000003052-8
sr-01000003052
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone;hydrochloride
2-{4-[(furan-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine hydrochloride
piperazin-1-yl)(furan-2-yl)
19237-84-4 (hcl)
prazosinhydrochloride
pressin and hypovase
Q27108060
BCP13643
methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-2-furanyl-, hydrochloride (1:1)
SB17352
H11453
BA164294
2-[4-(furan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine hydrochloride
EN300-7388587
prazosin hydrochloride (usan:usp:jan)
duramipress
prazosin hydrochloride (ep monograph)
prazosin hydrochloride (usp monograph)
1-(4-amino-6,7-dimethoxy-quinazolin-2-yl)-4-(2-furoyl)piperazine monohydrochloride
prazosin hydrochloride (ep impurity)
prazosin hydrochloride (usp-rs)
dtxcid7095313
2-(4-(2-furoyl)piperazin-1-yl)-6,7-dimethoxyquinazolin-4-amine hydrochloride
prazosin hydrochloride (mart.)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (71)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency17.74070.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency31.62280.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency23.49770.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID2323
acid sphingomyelinaseHomo sapiens (human)Potency31.622814.125424.061339.8107AID504937
endonuclease IVEscherichia coliPotency15.84890.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency67.83350.100020.879379.4328AID588453; AID588456
ATAD5 protein, partialHomo sapiens (human)Potency23.72460.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency20.69980.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency14.12540.180013.557439.8107AID1460
thioredoxin glutathione reductaseSchistosoma mansoniPotency39.81070.100022.9075100.0000AID485364
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.30850.011212.4002100.0000AID1030
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency0.31620.28189.721235.4813AID2326
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency31.67040.001530.607315,848.9004AID1224821; AID1224823
67.9K proteinVaccinia virusPotency12.07890.00018.4406100.0000AID720579; AID720580
glucocerebrosidaseHomo sapiens (human)Potency28.18380.01268.156944.6684AID2101
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency79.43280.707936.904389.1251AID504333
alpha-galactosidaseHomo sapiens (human)Potency41.33634.466818.391635.4813AID1467; AID2107
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.81070.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency25.11890.540617.639296.1227AID2364
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency19.95260.036619.637650.1187AID1466; AID2242
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency23.934123.934123.934123.9341AID1967
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.30850.001815.663839.8107AID894
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency18.35640.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency112.20203.548119.542744.6684AID743266
flap endonuclease 1Homo sapiens (human)Potency39.81070.133725.412989.1251AID588795
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency79.43280.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency12.58930.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency7.36970.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency16.06990.004611.374133.4983AID463097; AID504364; AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency100.00000.031622.3146100.0000AID588579
survival motor neuron protein isoform dHomo sapiens (human)Potency25.11890.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.58930.031610.279239.8107AID884; AID885
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency28.18380.025911.239831.6228AID602313
lamin isoform A-delta10Homo sapiens (human)Potency24.03530.891312.067628.1838AID1459; AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency15.84890.316212.765731.6228AID881
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency19.95263.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency19.95263.548118.039535.4813AID1466
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency15.84890.00638.235039.8107AID881
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
TAR DNA-binding protein 43Homo sapiens (human)Potency0.56231.778316.208135.4813AID652104
GABA theta subunitRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mcl-1Homo sapiens (human)IC50 (µMol)54.00000.40007.134454.0000AID1418
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)IC50 (µMol)54.00000.00052.773925.1700AID1418
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)IC50 (µMol)54.00000.00052.891925.1700AID1418
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)IC50 (µMol)54.00000.00052.747825.1700AID1418
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)IC50 (µMol)54.00000.00052.780225.1700AID1418
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)IC50 (µMol)54.00000.00053.314249.5000AID1418
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki0.00350.00010.949010.0000AID401518
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Ki0.00350.00000.575110.0000AID401518
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki0.00350.00000.965010.0000AID401518
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LMP1 [Human herpesvirus 4]human gammaherpesvirus 4 (Epstein-Barr virus)AC5020.72200.068039.9389277.4300AID504861
DNA repair and recombination protein RAD54-like isoform 1Homo sapiens (human)AC5056.63000.814019.311978.9500AID651657
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (80)

Assay IDTitleYearJournalArticle
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1133530Antihypertensive activity in anesthetized normotensive mongrel dog assessed as maximum decrease in blood pressure at 0.1 mg/kg, iv administered at 30 mins intervals1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Synthesis and identification of the major metabolites of prazosin formed in dog and rat.
AID168939Antihypertensive activity rating in conscious SHR after 6 hr post dose at 1 mg/kg (po)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID235726Selectivity as the ratio of pA2 value against alpha 1 receptor to that of alpha-2 receptor.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships for prazosin and WB 4101 analogues as alpha 1-adrenoreceptor antagonists.
AID186398Effect on mean blood pressure (initial) in renal hypertensive rats dosed at 3 mg/kg, po1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID1133531Antihypertensive activity in anesthetized normotensive mongrel dog assessed as maximum decrease in blood pressure at 0.4 mg/kg, iv administered at 30 mins intervals1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Synthesis and identification of the major metabolites of prazosin formed in dog and rat.
AID168932Antihypertensive activity rating in conscious SHR after 24 hr post dose at 3 mg/kg (po)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID569458Vasodilatory activity in Wistar rat aortic rings without endothelium assessed as reduction in norepinephrine hydrochloride-induced vasoconstriction2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Molecular modeling study and synthesis of quinazolinone-arylpiperazine derivatives as α1-adrenoreceptor antagonists.
AID658000Vasorelaxant activity in Wister rat thoracic aorta rings assessed as reduction in maximal noradrenaline-induced spasms2012European journal of medicinal chemistry, Jun, Volume: 52Synthesis, vasorelaxant activity, and molecular modeling study of some new phthalazine derivatives.
AID441358Displacement of [3H]prazosin from adrenergic Alpha-1B receptor in Wistar rat liver membrane after 60 mins2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Further studies on arylpiperazinyl alkyl pyridazinones: discovery of an exceptionally potent, orally active, antinociceptive agent in thermally induced pain.
AID173531Maximum percent decrease in blood pressure in SHR dosed at 0.3 mg/kg (hour post dose in parentheses)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID168788Antihypertensive activity determined as percent fall in blood pressure after 4 hours in spontaneously hypertensive rats administered with 10 mg/kg, (po)1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and antihypertensive activity of a series of 4-amino-6,7-dimethoxyquinazoline derivatives.
AID401518Displacement of radioligand from rat alpha1 adrenergic receptor by liquid scintillation spectrometry1997Journal of natural products, Apr, Volume: 60, Issue:4
Perhydrogenation of tabersonine, ans Aspidiosperma indole alkaloid.
AID188458Compound was tested for alpha-adrenoceptor blocking activity by its ability to antagonize norepinephrine contraction in the rat thoracic aorta1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID168928Antihypertensive activity rating in conscious SHR after 1 hr post dose at 3 mg/kg (po)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID167468Minimum effective dose level to give significant blood pressure lowering effect in normotensive rabbits after administering intravenously1980Journal of medicinal chemistry, Jul, Volume: 23, Issue:7
Synthesis and blood pressure lowering activity of 3-(substituted-amino)-1,2,4-benzothiadiazine 1-oxide derivatives.
AID186386Effect on blood pressure in renal hypertensive rats dosed at 10 mg/kg, po after 3 h1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID168929Antihypertensive activity rating in conscious SHR after 24 hr post dose at 0.3 mg/kg (po)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID172176Percentage blood pressure lowering in spontaneously hypertensive rats within 3 hr of intraperitoneal administration at 0.5 mg/kg1980Journal of medicinal chemistry, Jul, Volume: 23, Issue:7
Synthesis and blood pressure lowering activity of 3-(substituted-amino)-1,2,4-benzothiadiazine 1-oxide derivatives.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1133523Drug metabolism in rat assessed as parent compound level in bile1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Synthesis and identification of the major metabolites of prazosin formed in dog and rat.
AID186385Effect on blood pressure in renal hypertensive rats dosed at 10 mg/kg, po after 24 h1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID186384Effect on blood pressure in renal hypertensive rats dosed at 10mg/kg, po after 1 h1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID168937Antihypertensive activity rating in conscious SHR after 6 hr post dose at 0.3 mg/kg (po)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID186396Effect on blood pressure in renal hypertensive rats dosed at 3 mg/kg, po after 6 h1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID168790Antihypertensive activity rating in conscious SHR after 1 hr post dose at 0.3 mg/kg (po)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID1133522Drug metabolism in rat assessed as parent compound level in urine1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Synthesis and identification of the major metabolites of prazosin formed in dog and rat.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID600928Vasodilatory activity in Wistar rat thoracic aorta rings assessed as inhibition of norepinephrine hydrochloride-induced contraction2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Facile synthesis, vasorelaxant properties and molecular modeling studies of 2-amino-8a-methoxy-4H-pyrano[3,2-c]pyridine-3-carbonitriles.
AID186387Effect on blood pressure in renal hypertensive rats dosed at 10mg/kg, po after 6 h1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1133525Drug metabolism in dog assessed as parent compound level in bile1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Synthesis and identification of the major metabolites of prazosin formed in dog and rat.
AID168786Antihypertensive activity determined as percent fall in blood pressure after 2 hr in spontaneously hypertensive rats administered with 10 mg/kg (po)1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and antihypertensive activity of a series of 4-amino-6,7-dimethoxyquinazoline derivatives.
AID168787Antihypertensive activity determined as percent fall in blood pressure after 2 hr in spontaneously hypertensive rats administered with 3 mg/kg (po)1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and antihypertensive activity of a series of 4-amino-6,7-dimethoxyquinazoline derivatives.
AID186394Effect on blood pressure in renal hypertensive rats dosed at 3 mg/kg, po after 24 h1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID569457Hypotensive activity in normotensive cat assessed as reduction in diastolic blood pressure at 500 mg/kg, iv2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Molecular modeling study and synthesis of quinazolinone-arylpiperazine derivatives as α1-adrenoreceptor antagonists.
AID173513Maximum percent decrease in blood pressure in SHR dosed at 3 mg/kg (hour post dose in parentheses)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID569456Hypotensive activity in normotensive cat assessed as reduction in systolic blood pressure at 500 mg/kg, iv2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Molecular modeling study and synthesis of quinazolinone-arylpiperazine derivatives as α1-adrenoreceptor antagonists.
AID186393Effect on blood pressure in renal hypertensive rats dosed at 3 mg/kg, po after 1 h1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID196662Alpha-1-Adrenoceptor blocking activity as antagonism of (-)-norepinephrine induced contractions of epididymal vas deferens1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships for prazosin and WB 4101 analogues as alpha 1-adrenoreceptor antagonists.
AID168935Antihypertensive activity rating in conscious SHR after 3 hr post dose at 1 mg/kg (po)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID1133524Drug metabolism in dog assessed as parent compound level in urine1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Synthesis and identification of the major metabolites of prazosin formed in dog and rat.
AID186395Effect on blood pressure in renal hypertensive rats dosed at 3 mg/kg, po after 3 h1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID231250Potency ratio in rat thoracic aorta1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID168933Antihypertensive activity rating in conscious SHR after 3 hr post dose at 0.3 mg/kg (po)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID168940Antihypertensive activity rating in conscious SHR after 6 hr post dose at 3 mg/kg (po)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID441357Displacement of [3H]prazosin from adrenergic alpha1A receptor in Wistar rat submaxillary gland after 60 mins2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Further studies on arylpiperazinyl alkyl pyridazinones: discovery of an exceptionally potent, orally active, antinociceptive agent in thermally induced pain.
AID168789Antihypertensive activity determined as percent fall in blood pressure after 4 hours in spontaneously hypertensive rats administered with 3 mg/kg, (po)1986Journal of medicinal chemistry, Jan, Volume: 29, Issue:1
Synthesis and antihypertensive activity of a series of 4-amino-6,7-dimethoxyquinazoline derivatives.
AID168792Antihypertensive activity rating in conscious SHR after 1 hr post dose at 1 mg/kg (po)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID168931Antihypertensive activity rating in conscious SHR after 24 hr post dose at 1 mg/kg (po)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID1133532Antihypertensive activity in anesthetized normotensive mongrel dog assessed as maximum decrease in blood pressure at 1 mg/kg, iv administered at 30 mins intervals1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Synthesis and identification of the major metabolites of prazosin formed in dog and rat.
AID197109Alpha-2-adrenoceptor blocking activity was determined by antagonism of clonidine induced depression of the twitch responses of the field stimulated prostatic portion of the vas deferens and the potency was expressed as pA2.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships for prazosin and WB 4101 analogues as alpha 1-adrenoreceptor antagonists.
AID168936Antihypertensive activity rating in conscious SHR after 3 h post dose at 3 mg/kg (po)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID173532Maximum percent decrease in blood pressure in SHR dosed at 1 mg/kg (hour post dose in parentheses)1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID186378Effect on blood pressure (initial) in renal hypertensive rats dosed at 10mg/kg, po1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Pyrimidine derivatives. 4. Synthesis and antihypertensive activity of 4-amino-2-(4-cinnamoylpiperazino)-6,7-dimethoxyquinazoline derivatives.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (20.83)18.7374
1990's1 (4.17)18.2507
2000's4 (16.67)29.6817
2010's12 (50.00)24.3611
2020's2 (8.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 70.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index70.18 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index114.41 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (70.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]